Evolent Health, Inc $EVH Shares Sold by Philosophy Capital Management LLC

Key Points

• Philosophy Capital Management LLC reduced its stake in Evolent Health, Inc by 46.0%, holding 521,192 shares after selling 443,976 shares in the first quarter.
• Several institutional investors increased their positions, including US Bancorp DE with a 291.0% increase and Signaturefd LLC by 400.6%.
• Evolent Health posted a net loss of ($0.10) per share for the last quarter, falling short of analysts' expectations and reporting a 31.3% decline in revenue year-over-year.

Philosophy Capital Management LLC trimmed its position in shares of Evolent Health, Inc (NYSE:EVH - Free Report) by 46.0% in the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 521,192 shares of the technology company's stock after selling 443,976 shares during the quarter. Philosophy Capital Management LLC owned 0.45% of Evolent Health worth $4,936,000 at the end of the most recent quarter.

Other institutional investors also recently bought and sold shares of the company. Banque Cantonale Vaudoise acquired a new stake in shares of Evolent Health during the first quarter worth about $25,000. Rhumbline Advisers lifted its holdings in Evolent Health by 2.1% during the 1st quarter. Rhumbline Advisers now owns 169,918 shares of the technology company's stock worth $1,609,000 after buying an additional 3,527 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its position in Evolent Health by 2.9% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 128,527 shares of the technology company's stock valued at $1,217,000 after buying an additional 3,572 shares during the period. US Bancorp DE boosted its position in Evolent Health by 291.0% in the 1st quarter. US Bancorp DE now owns 5,153 shares of the technology company's stock valued at $49,000 after buying an additional 3,835 shares during the period. Finally, Signaturefd LLC grew its stake in shares of Evolent Health by 400.6% in the first quarter. Signaturefd LLC now owns 7,043 shares of the technology company's stock worth $67,000 after acquiring an additional 5,636 shares in the last quarter.

Evolent Health Stock Down 7.6%

EVH stock traded down $0.76 during trading on Wednesday, hitting $9.23. 1,700,667 shares of the company's stock were exchanged, compared to its average volume of 2,659,674. The business has a 50-day moving average price of $9.98 and a two-hundred day moving average price of $9.52. The company has a current ratio of 1.01, a quick ratio of 1.01 and a debt-to-equity ratio of 0.72. The stock has a market capitalization of $1.08 billion, a price-to-earnings ratio of -5.73 and a beta of 0.73. Evolent Health, Inc has a 52-week low of $7.06 and a 52-week high of $31.80.

Evolent Health (NYSE:EVH - Get Free Report) last released its quarterly earnings data on Thursday, August 7th. The technology company reported ($0.10) earnings per share for the quarter, missing analysts' consensus estimates of $0.10 by ($0.20). Evolent Health had a positive return on equity of 1.83% and a negative net margin of 5.94%.The company had revenue of $444.33 million for the quarter, compared to analyst estimates of $459.43 million. During the same period in the previous year, the business posted $0.30 EPS. The firm's revenue for the quarter was down 31.3% compared to the same quarter last year. Evolent Health has set its Q3 2025 guidance at EPS. As a group, equities research analysts expect that Evolent Health, Inc will post 0.08 EPS for the current year.

Wall Street Analyst Weigh In

A number of research analysts recently issued reports on the company. Truist Financial lifted their target price on Evolent Health from $14.00 to $16.00 and gave the company a "buy" rating in a report on Thursday, July 17th. Needham & Company LLC reiterated a "buy" rating and issued a $15.00 price objective on shares of Evolent Health in a research note on Tuesday, May 13th. JMP Securities restated a "market outperform" rating and set a $13.00 target price on shares of Evolent Health in a research note on Friday, June 20th. Piper Sandler lifted their price target on shares of Evolent Health from $16.00 to $18.00 and gave the stock an "overweight" rating in a research note on Thursday, August 28th. Finally, Canaccord Genuity Group reiterated a "buy" rating and set a $16.00 price target on shares of Evolent Health in a report on Tuesday. One equities research analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and one has assigned a Hold rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of "Buy" and a consensus target price of $17.43.

Evolent Health Profile

Evolent Health, Inc, through its subsidiary, Evolent Health LLC, offers specialty care management services in oncology, cardiology, and musculoskeletal markets in the United States. The company provides platform for health plan administration and value-based business infrastructure. It offers administrative services, such as health plan services, pharmacy benefits management, risk management, analytics and reporting, and leadership and management; and Identifi, a proprietary technology system that aggregates and analyzes data, manages care workflows, and engages patients.